News

Filter

Shire's ADHA drug Elvanse accepted for NHS use in Scotland; UK guidance on fidaxomicin

14-05-2013

Ireland-headquartered Shire plc (LSE: SHP) said yesterday (May 13) that its single-daily dose long-acting…

Antibiotics and Infectious diseasesAstellas PharmaDificlirElvanseEuropefidaxomicinNeurologicalPharmaceuticalRegulationShire

IQWiG finds no added proven benefit for Astellas' fidaxomicin in Clostridium difficile infection

23-04-2013

In an early benefit assessment under Germany's Act on the Reform of the Market for Medicinal Products…

Antibiotics and Infectious diseasesAstellas PharmaDificidDificlirfidaxomicinPharmaceuticalPricingRegulation

Optimer Pharma could earn $90 million from new Astellas deal

30-03-2012

US firm Optimer Pharmaceuticals (Nasdaq: OPTR) has entered into a second deal with Japanese drug major…

Antibiotics and Infectious diseasesAsia-PacificAstellas PharmaDificidfidaxomicinLicensingOptimer PharmaceuticalsPharmaceutical

Astellas to pay as much as 165 million euros for right to Optimer’s antibiotic fidaxomicin

08-02-2011

In a second licensing deal in less than a month, Japanese drug major Astellas (TYO: 4503) says that its…

Antibiotics and Infectious diseasesAstellas PharmaEuropefidaxomicinLicensingOptimer PharmaceuticalsPharmaceuticalRest of the World

COMPANY SPOTLIGHT

Menarini

Back to top